TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06521866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR: 25-60 Gy/5 Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR: 25-60 Gy/5 Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1
Study: NCT05845112

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP
Description: CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
Study: NCT05723315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human B-type natriuretic peptide
Description: The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
Study: NCT05861804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Nerve Block
Description: Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
Study: NCT06382337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A : ice cream cone technique
Description: collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
Study: NCT04791592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection, ultrasound-guided bilateral PIF block.
Description: PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection, ultrasound-guided bilateral TTMP block.
Description: TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit.
Study: NCT06382337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B : the vestibular socket therapy
Description: cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
Study: NCT05486390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge, health coaching and shared decision-making
Description: The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making.
Study: NCT06104137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: course (MOOC) patient education
Description: this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard patient consent process
Description: standard consenting and shared decision making in the clinic
Study: NCT05434273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HE programme
Description: Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
Study: NCT05690425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402 Injection
Description: Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
Study: NCT05173376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion size manipulation
Description: The intervention was administered via changing portion sizes of foods served to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion size manipulation
Description: The intervention was administered via changing portion sizes of foods served to participants.
Study: NCT05893719

Intervention type: DEVICE
Intervention: iNedit, iNdeep, iNtercept
Description: Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
Study: NCT05284136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crohn's disease exclusion diet (CDED)
Description: 16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
Study: NCT05600205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOAL!
Description: GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
Study: NCT05136846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: Given IV or SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT06419517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-triggered ES
Description: The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
Study: NCT05293431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Alternate Current Stimulation
Description: tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation will simulated the real tACS stimulation
Study: NCT06419517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
Study: NCT05580380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Relationship
Description: In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Relationship
Description: A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
Study: NCT04594798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: IV 1.8 mg/kg per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV 375 mg/m2 per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV 400 mg/m2 per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV 25 mg/m2 per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: PO 40 mg/m2 per cycle
Study: NCT04716153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial sensory rehabilitation workshops
Description: A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified.

Intervention type: OTHER
Group type: OTHER
Intervention: Tests and Questionnaire
Description: fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tests and Questionnaire
Description: fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
Study: NCT05130138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Description: Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
Study: NCT06082674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vayu bCPAP
Description: The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilator Driven CPAP
Description: Mechanical Ventilator Driven CPAP
Study: NCT04750135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin 500 mg TID Oral Tablet
Description: biguanides derivatives

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05174585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JAB-BX102 (anti-CD73 monoclonal antibody)
Description: Administered by intravenous infusion (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JAB-BX102 (anti-CD73 monoclonal antibody)
Description: Administered by intravenous infusion (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (anti-PD-1 monoclonal antibody)
Description: Administered by intravenous infusion (IV)
Study: NCT05924139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: 6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules per day of coconut oil
Study: NCT06093464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound A (Hinoki essential oil)
Description: Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound A (Hinoki essential oil)
Description: Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound A (Hinoki essential oil)
Description: Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound B (Lemon essential oil)
Description: Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound B (Lemon essential oil)
Description: Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound B (Lemon essential oil)
Description: Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound C (Control/Water)
Description: Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound C (Control/Water)
Description: Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound C (Control/Water)
Description: Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).